BID and cancer: Lack of significant differences in the expression of BID in histopathologically diverse forms of cancer (60.0% versus 42.9%, NS) can be partly explained by the observations of Lee et al. [1], who showed that BID gene mutation is rare (6%) but is associated with patients' resistance to chemotherapy.